{"uid":"cap_W1xB6UOSQlkS07Mb0PTCp","slug":"clinicalintelpulse-sponsor-intel-9c6649b2","name":"ClinicalIntelPulse Sponsor Intel","description":"Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents.","url":"https://clinicalintelpulse.vercel.app/api/clinical/sponsor-intel","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"focus":{"type":"string"},"sponsor":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"fda_approvals":[{"drug":"Patisiran (Onpattro)","type":"NDA","approved":"2018","indication":"hATTR polyneuropathy","first_in_class":true},{"drug":"Givosiran (Givlaari)","type":"NDA","approved":"2019","indication":"Acute hepatic porphyria"}],"phase3_assets":[{"drug":"Vutrisiran (Amvuttra)","nctId":"NCT04153149","status":"ACTIVE_NOT_RECRUITING","condition":"ATTR Cardiomyopathy","completion":"2025-Q3","significance":"Key label expansion into ATTR-CM — $3B+ market"}],"query_summary":{"focus":"all","sponsor":"Alnylam Pharmaceuticals"},"pipeline_summary":{"phase1_count":8,"phase2_count":9,"phase3_count":6,"total_active_trials":23,"primary_therapeutic_areas":["Rare genetic diseases (TTR, PH1, AHP)","Cardiovascular (inclisiran)","CNS (Huntington's)"]},"investment_signals":{"risks":["Pricing pressure in rare disease","RNAi delivery competition from Arrowhead"],"near_term_catalysts":["HELIOS-B ATTR-CM readout 2025","ALN-APP Phase 2 for early Alzheimer's"],"pipeline_value_estimate":"$12-18B risk-adjusted NPV"},"competitive_position":"Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.","partnership_activity":"Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+."}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.2","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.2/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_3oxFJRMtoG4TfxIuyXXBg","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.2","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Full pipeline analysis for a pharma or biotech company — trial counts by phase, therapeutic-area coverage, FDA history, partnerships, and competitive positioning.","exampleAgentPrompt":"Pull the full ClinicalIntelPulse sponsor intel profile for Regeneron — I need their trial count by phase, therapeutic area coverage, FDA history, and competitive positioning for an M&A due diligence review.","exampleUseCases":null,"resultDescription":"A structured report covering the sponsor's clinical trial pipeline broken down by phase, the therapeutic areas they are active in, their FDA approval and rejection history, known partnerships or licensing arrangements, and how they are positioned relative to competitors — formatted for investor or M&A decision-making.","failureModes":["Unknown or misspelled company name returns empty or low-confidence results","Small private biotechs with limited trial registrations may have sparse data","Payment of 0.2 USDC not fulfilled results in 402 Payment Required error","Rate limiting or API unavailability returns 5xx error","Company with recently rebranded name may not resolve correctly"],"whenToPreferThis":"Use this endpoint when you need a comprehensive, multi-dimensional view of a single pharma or biotech sponsor's pipeline — covering trial phases, therapeutic focus, regulatory track record, and competitive context. Prefer this over disease-specific endpoints when the analysis is company-centric rather than indication-centric, especially for investor due diligence, M&A screening, or partnership evaluation.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-15T12:43:07.342Z","isFirstParty":false}